Southlake, TX, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that the Centers for Medicare & Medicaid Services (CMS) has included AI-ECG technology in the 2025 Hospital Outpatient Prospective Payment System (OPPS) final rule under assignment ...

Core Insights - Limaca Medical Ltd.'s Precision-GI™ motorized endoscopic biopsy device has received transitional pass-through (TPT) payment approval from the Centers for Medicare & Medicaid Services (CMS), enhancing patient access to this innovative technology starting January 1, 2025 [1][2] - The Precision-GI™ device aims to improve biopsy results for patients with suspected gastrointestinal cancers, including pancreatic and liver cancers, and has previously received FDA Breakthrough Device Designation and clearance [1][2] Company Overview - Limaca Medical is an Israel-based company focused on enhancing endoscopic biopsy results for patients with potentially life-threatening cancers, supported by various investors including the Israeli Innovation Authority and The Trendlines Group [5] - The company is also pursuing market entry in Japan in collaboration with HekaBio [4][5] Product Details - The Precision-GI™ device features a motorized, automated, rotating cutting mechanism that allows for superior tissue acquisition quality, reducing blood content and procedure time compared to traditional endoscopic biopsy devices [3] - The device has begun its U.S. market entry after performing its first cases in September 2024, addressing the significant global incidence of pancreatic cancer, which recorded 510,992 new cases in 2022 [4]

Analyst’s Disclosure: I/we have a beneficial long position in the shares of STXS, DCTH either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. I could invest in AVITA Medical or Myomo over the next few months, but won't over the next 2 weeks.Seeking Alpha's Disclosure: Past perf ...

– TULSA to stand above all other covered prostate disease treatment modalities at Urology Level 7 reimbursement – – First-time CPT® code reimbursement for TULSA to be effective January 1, 2025 – TORONTO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that U.S. Centers for Medicare and Med ...

MELBOURNE, Australia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today welcomes the announcement by the United States (U.S.) Centers for Medicare & Medicaid Services (CMS) that it will pay separately for specialized diagnostic radiopharmaceuticals1 for Medicare Fee for Service patients in the hospital outpatient setting, beyond the transitional pass-through payment period (“pass-through”). This is a significant decision for patients and hospitals, with the ...

The Symplicity ™ blood pressure procedure offers patients a new adjunct approach to lowering blood pressure GALWAY, Ireland, Nov. 1, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the Centers for Medicare & Medicaid Services (CMS) has granted transitional pass-through (TPT) payment for the Medtronic Symplicity Spyral™ renal denervation (RDN) catheter, used in the Symplicity™ blood pressure procedure, under the Medicare Hospital Outpatient Prosp ...

NEW YORK and TOKYO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- HeartCore Enterprises, Inc. (Nasdaq: HTCR) (“HeartCore” or “the Company”), a leading enterprise software and data consulting services company based in Tokyo, announced a correction to a number in the second paragraph of its press release sent out on October 30, 2024. In the release, the sentence read: “The Company projects 115% sales growth across its software business as a result of this new transition.” The release has been corrected to read: “The Comp ...

CMS Energy (CMS) reported $1.74 billion in revenue for the quarter ended September 2024, representing a year-over-year increase of 4.2%. EPS of $0.84 for the same period compares to $0.61 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $1.83 billion, representing a surprise of -4.86%. The company delivered an EPS surprise of +7.69%, with the consensus EPS estimate being $0.78.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and h ...

CMS Energy Corporation (NYSE:CMS) Q3 2024 Earnings Conference Call October 31, 2024 9:30 AM ET Company Participants Jason Shore - Treasurer & VP, IR Garrick Rochow - President & CEO Rejji Hayes - EVP & CFO Conference Call Participants Shar Pourreza - Guggenheim Partners Jeremy Tonet - JPMorgan Ross Fowler - Bank of America Julien Dumoulin-Smith - Jefferies Travis Miller - Morningstar Michael Sullivan - Wolfe Research Andrew Weisel - Scotiabank Angie Storozynski - Seaport Anthony Crowdell - Mizuho Operator G ...

CMS Energy Corporation (CMS) reported third-quarter 2024 earnings per share (EPS) of 84 cents, which beat the Zacks Consensus Estimate of 78 cents by 7.7%. The bottom line also improved 40% from 60 cents in the prior-year quarter. The year-over-year improvement can be attributed to higher revenues and operating income.RevenuesOperating revenues totaled $1.74 billion, which lagged the Zacks Consensus Estimate of $1.83 billion by 4.9%. The top line, however, increased 4.2% on a year-over-year basis.Operationa ...